Adjuvant chemotherapy in upper tract urothelial cancer (the POUT trial): a phase 3, open-label, randomised controlled trial A Birtle and others The Lancet, 2020. Volume 395, Issue 10232, Page ...

Updated guidance offers evidence-based strategies to optimize the diagnosis and treatment of non-metastatic upper tract ...

Results from a small retrospective analysis of patients with upper tract urothelial carcinoma lesions were shared at the 2025 ASCO Genitourinary Cancers Symposium. Padcev plus Keytruda showed ...

While randomized comparative trials are needed, a relatively new treatment option for upper urinary tract cancers shows promise for lowering long-term recurrence in many patients with low-grade ...

A review of management options for upper urinary tract TCC. The authors discuss choosing the most appropriate treatment based on patient characteristics and tumor recurrence in the bladder.

The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, ...

UTUC is a tumor type that is similar to bladder cancer, but the tumor is located in the renal pelvis, arising from the cells lining the kidneys and the ureters. It has similar causes as bladder cancer ...

UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis ...

"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer," said ...

Raman and colleagues reported that, following definitive surgical resection of upper-tract TCC (nephroureterectomy or segmental ureterectomy), bladder tumors developed in 44% of patients at a mean ...